GTPase Activity Plays a Key Role in the Pathobiology of LRRK2

English version České info

Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are associated with late-onset, autosomal-dominant, familial Parkinson's disease (PD) and also contribute to sporadic disease. The LRRK2 gene encodes a large protein with multiple domains, including functional Roc GTPase and protein kinase domains. Mutations in LRRK2 most likely cause disease through a toxic gain-of-function mechanism. The expression of human LRRK2 variants in cultured primary neurons induces toxicity that is dependent on intact GTP binding or kinase activities. However, the mechanism(s) underlying LRRK2-induced neuronal toxicity is poorly understood, and the contribution of GTPase and/or kinase activity to LRRK2 pathobiology is not well defined. To explore the pathobiology of LRRK2, we have developed a model of LRRK2 cytotoxicity in the baker's yeast Saccharomyces cerevisiae. Protein domain analysis in this model reveals that expression of GTPase domain-containing fragments of human LRRK2 are toxic. LRRK2 toxicity in yeast can be modulated by altering GTPase activity and is closely associated with defects in endocytic vesicular trafficking and autophagy. These truncated LRRK2 variants induce similar toxicity in both yeast and primary neuronal models and cause similar vesicular defects in yeast as full-length LRRK2 causes in primary neurons. The toxicity induced by truncated LRRK2 variants in yeast acts through a mechanism distinct from toxicity induced by human α-synuclein. A genome-wide genetic screen identified modifiers of LRRK2-induced toxicity in yeast including components of vesicular trafficking pathways, which can also modulate the trafficking defects caused by expression of truncated LRRK2 variants. Our results provide insight into the basic pathobiology of LRRK2 and suggest that the GTPase domain may contribute to the toxicity of LRRK2. These findings may guide future therapeutic strategies aimed at attenuating LRRK2-mediated neurodegeneration.

Vyšlo v časopise: GTPase Activity Plays a Key Role in the Pathobiology of LRRK2. PLoS Genet 6(4): e32767. doi:10.1371/journal.pgen.1000902
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pgen.1000902

Souhrn

Zdroje

1. LangAE

LozanoAM

1998 Parkinson's disease. Second of two parts. N Engl J Med 339 1130 1143

2. LangAE

LozanoAM

1998 Parkinson's disease. First of two parts. N Engl J Med 339 1044 1053

3. GiassonBI

CovyJP

BoniniNM

HurtigHI

FarrerMJ

2006 Biochemical and pathological characterization of Lrrk2. Ann Neurol 59 315 322

4. HealyDG

WoodNW

SchapiraAH

2008 Test for LRRK2 mutations in patients with Parkinson's disease. Pract Neurol 8 381 385

5. Paisan-RuizC

JainS

EvansEW

GilksWP

SimonJ

2004 Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44 595 600

6. RossOA

ToftM

WhittleAJ

JohnsonJL

PapapetropoulosS

2006 Lrrk2 and Lewy body disease. Ann Neurol 59 388 393

7. ZimprichA

BiskupS

LeitnerP

LichtnerP

FarrerM

2004 Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44 601 607

8. GilksWP

Abou-SleimanPM

GandhiS

JainS

SingletonA

2005 A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet 365 415 416

9. HaugarvollK

WszolekZK

2006 PARK8 LRRK2 parkinsonism. Curr Neurol Neurosci Rep 6 287 294

10. CooksonMR

DauerW

DawsonT

FonEA

GuoM

2007 The roles of kinases in familial Parkinson's disease. J Neurosci 27 11865 11868

11. MataIF

WedemeyerWJ

FarrerMJ

TaylorJP

GalloKA

2006 LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci 29 286 293

12. GloecknerCJ

KinklN

SchumacherA

BraunRJ

O'NeillE

2006 The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum Mol Genet 15 223 232

13. GreggioE

ZambranoI

KaganovichA

BeilinaA

TaymansJM

2008 The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation. J Biol Chem 283 16906 16914

14. GuoL

GandhiPN

WangW

PetersenRB

Wilson-DelfosseAL

2007 The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp Cell Res 313 3658 3670

15. ItoG

OkaiT

FujinoG

TakedaK

IchijoH

2007 GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46 1380 1388

16. JaleelM

NicholsRJ

DeakM

CampbellDG

GillardonF

2007 LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem J 405 307 317

17. Luzon-ToroB

Rubio de la TorreE

DelgadoA

Perez-TurJ

HilfikerS

2007 Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum Mol Genet 16 2031 2039

18. WestAB

MooreDJ

BiskupS

BugayenkoA

SmithWW

2005 Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 102 16842 16847

19. LewisPA

GreggioE

BeilinaA

JainS

BakerA

2007 The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem Biophys Res Commun 357 668 671

20. LiX

TanYC

PouloseS

OlanowCW

HuangXY

2007 Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J Neurochem 103 238 247

21. SmithWW

PeiZ

JiangH

DawsonVL

DawsonTM

2006 Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat Neurosci 9 1231 1233

22. WestAB

MooreDJ

ChoiC

AndrabiSA

LiX

2007 Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum Mol Genet 16 223 232

23. GreggioE

JainS

KingsburyA

BandopadhyayR

LewisP

2006 Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol Dis 23 329 341

24. MacLeodD

DowmanJ

HammondR

LeeteT

InoueK

2006 The familial Parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52 587 593

25. LiuZ

WangX

YuY

LiX

WangT

2008 A Drosophila model for LRRK2-linked parkinsonism. Proc Natl Acad Sci U S A 105 2693 2698

26. NgCH

MokSZ

KohC

OuyangX

FivazML

2009 Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 29 11257 11262

27. VenderovaK

KabbachG

Abdel-MessihE

ZhangY

ParksRJ

2009 Leucine-rich repeat kinase interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease. Hum Mol Genet

28. LiY

LiuW

OoTF

WangL

TangY

2009 Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinson's disease. Nat Neurosci 12 826 828

29. TongY

PisaniA

MartellaG

KarouaniM

YamaguchiH

2009 R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A 106 14622 14627

30. CooperAA

GitlerAD

CashikarA

HaynesCM

HillKJ

2006 Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 313 324 328

31. GitlerAD

BevisBJ

ShorterJ

StrathearnKE

HamamichiS

2008 The Parkinson's disease protein alpha-synuclein disrupts cellular Rab homeostasis. Proc Natl Acad Sci U S A 105 145 150

32. OuteiroTF

LindquistS

2003 Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302 1772 1775

33. WilsonMA

St AmourCV

CollinsJL

RingeD

PetskoGA

2004 The 1.8-A resolution crystal structure of YDR533Cp from Saccharomyces cerevisiae: a member of the DJ-1/ThiJ/PfpI superfamily. Proc Natl Acad Sci U S A 101 1531 1536

34. Alegre-AbarrateguiJ

AnsorgeO

EsiriM

Wade-MartinsR

2008 LRRK2 is a component of granular alpha-synuclein pathology in the brainstem of Parkinson's disease. Neuropathol Appl Neurobiol 34 272 283

35. MooreDJ

WestAB

DawsonVL

DawsonTM

2005 Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 28 57 87

36. SavittJM

DawsonVL

DawsonTM

2006 Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 116 1744 1754

37. SmithWW

PeiZ

JiangH

MooreDJ

LiangY

2005 Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc Natl Acad Sci U S A 102 18676 18681

38. HoCC

RideoutHJ

RibeE

TroyCM

DauerWT

2009 The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci 29 1011 1016

39. WillinghamS

OuteiroTF

DeVitMJ

LindquistSL

MuchowskiPJ

2003 Yeast genes that enhance the toxicity of a mutant huntingtin fragment or alpha-synuclein. Science 302 1769 1772

40. DengJ

LewisPA

GreggioE

SluchE

BeilinaA

2008 Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc Natl Acad Sci U S A 105 1499 1504

41. DiFigliaM

SappE

ChaseKO

DaviesSW

BatesGP

1997 Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 1990 1993

42. LiH

LiSH

JohnstonH

ShelbournePF

LiXJ

2000 Amino-terminal fragments of mutant huntingtin show selective accumulation in striatal neurons and synaptic toxicity. Nat Genet 25 385 389

43. LunkesA

LindenbergKS

Ben-HaiemL

WeberC

DevysD

2002 Proteases acting on mutant huntingtin generate cleaved products that differentially build up cytoplasmic and nuclear inclusions. Mol Cell 10 259 269

44. RossCA

2002 Polyglutamine pathogenesis: emergence of unifying mechanisms for Huntington's disease and related disorders. Neuron 35 819 822

45. JohnsonBS

McCafferyJM

LindquistS

GitlerAD

2008 A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity. Proc Natl Acad Sci U S A 105 6439 6444

46. ZhangYJ

XuYF

DickeyCA

BurattiE

BaralleF

2007 Progranulin mediates caspase-dependent cleavage of TAR DNA binding protein-43. J Neurosci 27 10530 10534

47. LiW

WestN

CollaE

PletnikovaO

TroncosoJC

2005 Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci U S A 102 2162 2167

48. MurrayIV

GiassonBI

QuinnSM

KoppakaV

AxelsenPH

2003 Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry 42 8530 8540

49. MiklossyJ

AraiT

GuoJP

KlegerisA

YuS

2006 LRRK2 expression in normal and pathologic human brain and in human cell lines. J Neuropathol Exp Neurol 65 953 963

50. Di FonzoA

Wu-ChouYH

LuCS

van DoeselaarM

SimonsEJ

2006 A common missense variant in the LRRK2 gene, Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7 133 138

51. BiskupS

MooreDJ

CelsiF

HigashiS

WestAB

2006 Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 60 557 569

52. HatanoT

KuboS

ImaiS

MaedaM

IshikawaK

2007 Leucine-rich repeat kinase 2 associates with lipid rafts. Hum Mol Genet 16 678 690

53. ShinN

JeongH

KwonJ

HeoHY

KwonJJ

2008 LRRK2 regulates synaptic vesicle endocytosis. Exp Cell Res 314 2055 2065

54. Sakaguchi-NakashimaA

MeirJY

JinY

MatsumotoK

HisamotoN

2007 LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr Biol 17 592 598

55. PloweyED

CherraSJ3rd

LiuYJ

ChuCT

2008 Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J Neurochem 105 1048 1056

56. Alegre-AbarrateguiJ

ChristianH

LufinoM

MutihacR

Lourenco VendaL

2009 LRRK2 regulates autophagic activity and localises to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet

57. GietzRD

WoodsRA

2002 Transformation of yeast by lithium acetate/single-stranded carrier DNA/polyethylene glycol method. Methods Enzymol 350 87 96

58. MumbergD

MullerR

FunkM

1994 Regulatable promoters of Saccharomyces cerevisiae: comparison of transcriptional activity and their use for heterologous expression. Nucleic Acids Res 22 5767 5768

59. HigashiS

BiskupS

WestAB

TrinkausD

DawsonVL

2007 Localization of Parkinson's disease-associated LRRK2 in normal and pathological human brain. Brain Res 1155 208 219

60. SchmittME

BrownTA

TrumpowerBL

1990 A rapid and simple method for preparation of RNA from Saccharomyces cerevisiae. Nucl Acids Res 18 3091 3092

61. Maguire-ZeissKA

BowersWJ

FederoffHJ

2001 HSV vector-mediated gene delivery to the central nervous system. Curr Opin Mol Ther 3 482 490

62. RiederSE

BantaLM

KohrerK

McCafferyJM

EmrSD

1996 Multilamellar endosome-like compartment accumulates in the yeast vps28 vacuolar protein sorting mutant. Mol Biol Cell 7 985 999

63. CorbettM

XiongY

BoyneJR

WrightDJ

MunroE

2006 IQGAP and mitotic exit network (MEN) proteins are required for cytokinesis and re-polarization of the actin cytoskeleton in the budding yeast, Saccharomyces cerevisiae. Eur J Cell Biol 85 1201 1215

64. TongAH

EvangelistaM

ParsonsAB

XuH

BaderGD

2001 Systematic genetic analysis with ordered arrays of yeast deletion mutants. Science 294 2364 2368

65. TongAH

BooneC

2006 Synthetic genetic array analysis in Saccharomyces cerevisiae. Methods Mol Biol 313 171 192